Skip to main content
. 2021 Nov 22;11:762288. doi: 10.3389/fonc.2021.762288

Figure 2.

Figure 2

Forest plots of the pooled hazard ratio for overall survival (A) and progression-free survival (B) and odds ratio for objective response rate (C) between doxorubicin/adriamycin plus ifosfamide combination chemotherapy and doxorubicin/adriamycin monotherapy.